These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 34253568)
21. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. Wang Q; Liu F; Liu L Medicine (Baltimore); 2017 May; 96(18):e6369. PubMed ID: 28471952 [TBL] [Abstract][Full Text] [Related]
22. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis. Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153 [TBL] [Abstract][Full Text] [Related]
23. Prognostic Function of Programmed Cell Death-Ligand 1 in Esophageal Squamous Cell Carcinoma Patients Without Preoperative Therapy: A Systematic Review and Meta-Analysis. Cui H; Li Y; Li S; Liu G Front Oncol; 2021; 11():693886. PubMed ID: 34490091 [TBL] [Abstract][Full Text] [Related]
24. Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis. Li XS; Li JW; Li H; Jiang T Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32255189 [TBL] [Abstract][Full Text] [Related]
25. Soluble PD-L1 Concentration Is Proportional to the Expression of PD-L1 in Tissue and Is Associated with a Poor Prognosis in Esophageal Squamous Cell Carcinoma. Shiraishi T; Toyozumi T; Sakata H; Murakami K; Kano M; Matsumoto Y; Yokoyama M; Okada K; Kamata T; Ryuzaki T; Kinoshita K; Hirasawa S; Matsubara H Oncology; 2022; 100(1):39-47. PubMed ID: 34991094 [TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis. Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578 [TBL] [Abstract][Full Text] [Related]
27. Association between programmed cell death ligand 1 expression and thyroid cancer: A meta-analysis. Wan B; Deng P; Dai W; Wang P; Dong Z; Yang C; Tian J; Hu T; Yan K Medicine (Baltimore); 2021 Apr; 100(14):e25315. PubMed ID: 33832105 [TBL] [Abstract][Full Text] [Related]
28. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis. Li S; Chen L; Jiang J Medicine (Baltimore); 2019 Apr; 98(16):e15201. PubMed ID: 31008945 [TBL] [Abstract][Full Text] [Related]
29. Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis. Lenouvel D; González-Moles MÁ; Ruiz-Ávila I; Gonzalez-Ruiz L; Gonzalez-Ruiz I; Ramos-García P Oral Oncol; 2020 Jul; 106():104722. PubMed ID: 32330687 [TBL] [Abstract][Full Text] [Related]
30. D-dimer levels predict the treatment efficacy and prognosis of esophageal squamous cell carcinoma treated with PD-1/PD-L1 inhibitors. Wu Y; Liu X; Li H; Wang W; Ye L; Zhou Y; Chen D Int J Biol Markers; 2024 Sep; 39(3):209-216. PubMed ID: 38887052 [TBL] [Abstract][Full Text] [Related]
31. Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy. Huang TC; Liang CW; Li YI; Guo JC; Lin CC; Chen YJ; Cheng AL; Hsu CH J Cancer Res Clin Oncol; 2022 Jul; 148(7):1803-1811. PubMed ID: 34432128 [TBL] [Abstract][Full Text] [Related]
32. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis. Zhu X; Shanzhou Q; Li D; Pang X; Ma D BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782 [TBL] [Abstract][Full Text] [Related]
33. Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis. Xu J; Wang F; Yan Y; Zhang Y; Du Y; Sun G Am J Med Sci; 2020 Jun; 359(6):339-346. PubMed ID: 32498941 [TBL] [Abstract][Full Text] [Related]
34. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis. Li J; Wang P; Xu Y PLoS One; 2017; 12(6):e0179536. PubMed ID: 28604812 [TBL] [Abstract][Full Text] [Related]
35. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis. Qian X; Chen H; Tao Y Front Immunol; 2023; 14():1146898. PubMed ID: 37063822 [TBL] [Abstract][Full Text] [Related]
36. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma. Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840 [TBL] [Abstract][Full Text] [Related]
37. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma. Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003 [TBL] [Abstract][Full Text] [Related]
38. Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis. Zhang F; Gong W Int Immunopharmacol; 2020 Jun; 83():106481. PubMed ID: 32339986 [TBL] [Abstract][Full Text] [Related]
39. Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis. Wang S; Yuan B; Wang Y; Li M; Liu X; Cao J; Li C; Hu J Int J Colorectal Dis; 2021 Jan; 36(1):117-130. PubMed ID: 32910207 [TBL] [Abstract][Full Text] [Related]
40. The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. Wen Y; Chen Y; Duan X; Zhu W; Cai C; Deng T; Zeng G Clin Exp Med; 2019 Nov; 19(4):407-416. PubMed ID: 31407099 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]